The prognostic value of histological grade determined after neoadjuvant chemotherapy of breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Histological grade changes after neoadjuvant chemotherapy (NACT) in breast cancer. Post-treatment grade (yG) impacts survival but is not an independent prognostic factor, supporting its continued reporting by pathologists.
Area Of Science
- Oncology
- Pathology
- Breast Cancer Research
Background
- Histological grade is a known prognostic factor in breast cancer.
- Neoadjuvant chemotherapy (NACT) can alter tumor grade.
- Reporting post-NACT grade is recommended, but its prognostic value is unclear.
Purpose Of The Study
- To evaluate the prognostic impact of post-treatment histological grade (yG) in breast cancer patients.
- To determine if yG retains prognostic significance after NACT.
Main Methods
- Analysis of 355 breast cancer patients treated with NACT and surgery.
- Kaplan-Meier analysis, log-rank test, and Cox proportional hazards models.
- Comparison of survival outcomes based on pretreatment and post-treatment tumor grade.
Main Results
- 31% of patients showed a change in histological grade after NACT, with downgrading more frequent.
- Patients with yG3 tumors had significantly worse 5-year relapse-free and overall survival than yG1/yG2.
- Post-treatment grade (yG) lost its independent prognostic significance in multivariable analysis.
Conclusions
- Post-NACT histological grade demonstrates a prognostic impact on breast cancer survival.
- While not an independent prognosticator, yG reporting by pathologists after primary systemic treatment is supported.
- This supports the clinical utility of assessing tumor grade post-NACT.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
